Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RayzeBio, Inc.
Pfizer
National Institutes of Health Clinical Center (CC)
Pfizer
Assistance Publique - Hôpitaux de Paris
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Pfizer